Factors predicting the treatment frequency of ranibizumab injections during the second year in diabetic macular edema.

The cumulative doses of ranibizumab injections, CST, and hyperreflective walls in the foveal cystoid spaces at the 12-month visit are designated predictors of the treatment frequency of ranibizumab injections during the second year in DME.